Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 85Stomach Neoplasms 16Esophageal Neoplasms 14Neoplasms 10Cholangiocarcinoma 10Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 9Neoplasm Metastasis 8Adenocarcinoma Of Esophagus 8Esophageal Squamous Cell Carcinoma 7Endometrial Neoplasms 7Colorectal Neoplasms 7Pancreatic Adenocarcinoma 6Ovarian Neoplasms 6Lung Neoplasms 6Gallbladder Neoplasms 6Carcinoma, Ovarian Epithelial 6Adenocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4Prostatic Neoplasms 4Melanoma 4Biliary Tract Neoplasms 4Urinary Bladder Neoplasms 3Sarcoma 3Liver Neoplasms 3Gastric Adenocarcinoma 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Anus Neoplasms 3Advanced Pancreatic Cancer 3

Interventions

zolbetuximab 1trifluridine tipiracil drug combination 1tipiracil 1camrelizumab 1Trifluridine 1Taxes 1Oxaliplatin 1HMPL-013 1Docetaxel 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastric Cancer Adenocarcinoma Metastatic × Taxes × Gastrointestinal × Clear all
NCT07392346 2026-02-11

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

Chinese PLA General Hospital

Phase 2 Recruiting
68 enrolled
Gastrointestinal

Gastric Cancer Adenocarcinoma Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡